0001225208-20-007628.txt : 20200513 0001225208-20-007628.hdr.sgml : 20200513 20200513182849 ACCESSION NUMBER: 0001225208-20-007628 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200511 FILED AS OF DATE: 20200513 DATE AS OF CHANGE: 20200513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Szyman Catherine M. CENTRAL INDEX KEY: 0001438538 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15525 FILM NUMBER: 20874756 MAIL ADDRESS: STREET 1: C/O EDWARDS LIFESCIENCES CORPORATION STREET 2: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 FORMER NAME: FORMER CONFORMED NAME: Szyman Catherine M DATE OF NAME CHANGE: 20080625 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edwards Lifesciences Corp CENTRAL INDEX KEY: 0001099800 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 364316614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 9492502500 MAIL ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP. DATE OF NAME CHANGE: 20090225 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP DATE OF NAME CHANGE: 20000203 FORMER COMPANY: FORMER CONFORMED NAME: CVG CONTROLLED INC DATE OF NAME CHANGE: 19991126 4 1 doc4.xml X0306 4 2020-05-11 0001099800 Edwards Lifesciences Corp EW 0001438538 Szyman Catherine M. ONE EDWARDS WAY IRVINE CA 92614 1 CVP, Critical Care Common Stock 2020-05-11 4 M 0 5950.0000 0 A 18317.8898 D Common Stock 2020-05-11 4 F 0 548.0000 217.8400 D 17769.8898 D Common Stock 2020-05-11 4 F 0 2951.0000 217.8400 D 14818.8898 D Common Stock 2020-05-12 4 F 0 682.0000 225.0500 D 14136.8898 D Common Stock 2020-05-13 4 S 0 750.0000 216.9300 D 13386.8898 D Performance Rights 2020-05-11 4 M 0 5950.0000 0.0000 D 2020-05-11 Common Stock 5950.0000 0.0000 D On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Linda J. Park, Attorney-in-Fact 2020-05-13